Comparative cytotoxicity of 177Lu on various lung cancer cells and in vivo targeting of 177Lu-labeled cetuximab

被引：0
|
作者：
Li, Kehong [1 ,2 ]
Fan, Wenqi [2 ]
Yan, Jingxuan [1 ,2 ]
Wang, Jing [2 ,3 ,4 ]
Zhao, Peng [2 ]
Liao, Wei [2 ,4 ]
Yang, Yuchuan [2 ,3 ]
Yang, Xia [2 ,3 ,4 ]
Wei, Hongyuan [1 ,2 ]
Chen, Yue [1 ,4 ]
机构：
[1] Southwest Med Univ, Dept Nucl Med, Affiliated Hosp, Luzhou 646000, Peoples R China
[2] China Acad Engn Phys, Inst Nucl Phys & Chem, Mianyang 621900, Peoples R China
[3] Mianyang Cent Hosp, NHC Key Lab Nucl Technol Med Transformat, Mianyang 621900, Peoples R China
[4] Key Lab Nucl Med & Mol Imaging Sichuan Prov, Mianyang 621999, Peoples R China
来源：
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY | 2023年 / 332卷 / 06期
基金：
中国国家自然科学基金;
关键词：
Lung cancer; Radiosensitivity; Lutetium-177; Anti-EGFR antibody; Tumor targeting; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; NECK-CARCINOMA; EGFR MUTATIONS; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; RESISTANCE; RADIATION; SENSITIVITY; RESECTION;
D O I：
10.1007/s10967-023-08903-7
中图分类号：
O65 [分析化学];
学科分类号：
070302 ; 081704 ;
摘要：
Differences in cellular radiosensitivity and the binding affinity of radiopharmaceuticals could directly affect the radiotherapeutic effects. In this study, we investigated the radionuclide (Lu-177) induced radiosensitivity of serval non-small-cell lung cancer cells (NSCLCs) as well as the binding affinity of cetuximab to those cells. The apoptosis of NSCLCs caused by Lu-177 was related to the DNA double-strand damage and was cell-type dependent. We also proved that the introduction of Lu-177 to the antibody could enhance its cytotoxic effect on NSCLCs. The [Lu-177]Lu-DOTA-cetuximab could accumulate in the HCC827 tumor xenografts with excellent stability according to in vivo SPECT/CT imaging and the biodistribution results. The [Lu-177]Lu-DOTA-cetuximab showed high potential to be used for targeting diagnosis and radiotherapy in lung cancers.
引用
收藏
页码：2093 / 2102
页数：10
相关论文
共 50 条
  • [1] Comparative cytotoxicity of 177Lu on various lung cancer cells and in vivo targeting of 177Lu-labeled cetuximab
    Kehong Li
    Wenqi Fan
    Jingxuan Yan
    Jing Wang
    Peng Zhao
    Wei Liao
    Yuchuan Yang
    Xia Yang
    Hongyuan Wei
    Yue Chen
    [J]. Journal of Radioanalytical and Nuclear Chemistry, 2023, 332 : 2093 - 2102
  • [2] 177LU QUALITY ANALYSIS FOR AN EFFICIENT PREPARATION OF 177LU-LABELED COMPOUNDS.
    Zhernosekov, K.
    Geistlich, S.
    Blanc, A.
    Landolt, S.
    Turler, A.
    Schibli, R.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2012, 102 : S142 - S142
  • [3] Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody
    Ehlerding, Emily B.
    Lacognata, Saige
    Jiang, Dawei
    Ferreira, Carolina A.
    Goel, Shreya
    Hernandez, Reinier
    Jeffery, Justin J.
    Theuer, Charles P.
    Cai, Weibo
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (01) : 123 - 131
  • [4] Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody
    Emily B. Ehlerding
    Saige Lacognata
    Dawei Jiang
    Carolina A. Ferreira
    Shreya Goel
    Reinier Hernandez
    Justin J. Jeffery
    Charles P. Theuer
    Weibo Cai
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 123 - 131
  • [5] Prospects of medium specific activity 177Lu in targeted therapy of prostate cancer using 177Lu-labeled PSMA inhibitor
    Chakraborty, Sudipta
    Chakravarty, Rubel
    Shetty, Priyalata
    Vimalnath, K. V.
    Sen, Ishita B.
    Dash, Ashutosh
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2016, 59 (09): : 364 - 371
  • [6] 177Lu-DOTATATE: comparative study between 177Lu NRG/Netherlands and 177Lu ORNL/USA
    Caldeira Filho, Jose de Souza
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2010, 37 (06) : 691 - 692
  • [7] Development of a 177Lu-Labeled RGD Derivative for Targeting Angiogenesis
    Ju, Chang Hwan
    Jeong, Jae Min
    Lee, Yun-Sang
    Kim, Young Joo
    Lee, Byung Chul
    Lee, Dong Soo
    Chung, June-Key
    Lee, Myung Chul
    Jeong, Seo Young
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2010, 25 (06) : 687 - 691
  • [8] Targeting angiogenesis for radioimmunotherapy with 177Lu
    Ehlerding, Emily
    Jiang, Dawei
    Goel, Shreya
    Hernandez, Reinier
    Jeffery, Justin
    Cai, Weibo
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [9] [177Lu]Lu-labeled gold nanoparticles as tumor hypoxia targeting platforms
    Mittal, Sweety
    Mallia, Madhava
    Sharma, Rohit
    Sarma, Haladhar D.
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2021, 96-97 : S85 - S86
  • [10] On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor
    Das, Tapas
    Chakraborty, Sudipta
    Banerjee, Sharmila
    Venkatesh, Meera
    [J]. APPLIED RADIATION AND ISOTOPES, 2007, 65 (03) : 301 - 308
12345